Pharmacology of human experimental anxiety

Brazilian Journal of Medical and Biological Research

Volumn 36, Issue 4, 2003, Pages 421-432

  Graeff, F G ^a   Del Ben, C M ^a   Guimaraes F S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anxiety; Anxiety disorders; Anxiolytic drugs; Experimental anxiety; Humans

Indexed keywords

ALCOHOL; ALPRAZOLAM; ANXIOLYTIC AGENT; BENZODIAZEPINE; BUSPIRONE; CANNABIDIOL; CLOMIPRAMINE; DEXFENFLURAMINE; DIAZEPAM; FLUMAZENIL; FLUVOXAMINE; IPSAPIRONE; LORAZEPAM; MAPROTILINE; METERGOLINE; NABILONE; NEFAZODONE; PIPERAZINE DERIVATIVE; RITANSERIN; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR AFFECTING AGENT; TRYPTOPHAN;

ANXIETY DISORDER; AVERSIVE BEHAVIOR; COGNITION; COLOR; CONDITIONING; CONFLICT; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG SENSITIVITY; ECONOMIC ASPECT; EMOTIONALITY; EYELID REFLEX; HUMAN; MEDICAL ETHICS; NOISE; PANIC; PATHOPHYSIOLOGY; PREVALENCE; PSYCHOLOGIC TEST; PSYCHOMETRY; REVIEW; SEROTONINERGIC TRANSMISSION; SKIN CONDUCTANCE; SOCIAL PHOBIA; SPECIES DIFFERENCE; SPEECH; STARTLE REFLEX; TELEVISION CAMERA;

ANIMALIA;

EID: 0037720325     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2003000400003     Document Type: Review

References (58)

1. Graeff FG & Zangrossi Jr H (2002). Animal models of anxiety disorders. In: D'haenen H, den Boer JA, Westenberg H & Willner P (Editors), Textbook of Biological Psychiatry. John Wiley & Sons, London, UK, 879-893.
2. Janke W & Netter P (1983). Anxiolytic effects of drugs: approaches, methods and problems. Neuropsychobiology, 9: 33-40.
3. Gray JA & McNaughton N (2000). The Neuropsychology of Anxiety. Oxford University Press, Oxford, UK.
4. Bond AJ, James DC & Lader MH (1974). Physiological and psychological measures in anxious patients. Psychological Medicine, 4: 364-373.
5. Fowles DC (2000). Electrodermal hyporeactivity and antisocial behavior: does anxiety mediate the relationship? Journal of Affective Disorders, 61: 177-189.
6. Vila J & Beech HR (1977). Vulnerability and conditioning in relation to the human menstrual cycle. British Journal of Social and Clinical Psychology, 16: 69-75.
7. Wang M (1986). Changes in psychophysiological and conditioning variables during chlomethiazole-medicated and unmedicated ethanol withdrawal: preliminary report. Acta Psychiatrica Scandinavica, 73 (Suppl 329): 146-152.
8. Guimarães FS, Hellewell J, Hensman R, Wang M & Deakin JFW (1991). Characterization of a psychophysiological model of classical fear conditioning in healthy volunteers: influence of gender, instructions, personality and placebo. Psychopharmacology, 104: 231-236.
9. Hellewell JS, Guimarães FS, Wang M & Deakin JF (1999). Comparison of buspirone with diazepam and fluvoxamine on aversive classical conditioning in humans. Journal of Psychopharmacology, 13: 122-127.
10. Hensman R, Guimarães FS, Wang M & Deakin JFW (1991). The effects of ritanserin on aversive classical conditioning in humans. Psychopharmacology, 104: 220-224.
11. Silva FT & Leite JR (2000). Physiological modifications and increase in state anxiety in volunteers submitted to the Stroop Color-Word Interference Test: A preliminary study. Physiology and Behavior, 70: 113-118.
12. Hetem LA, de Souza CJ, Guimarães FS, Zuardi AW & Graeff FG (1996). Effect of d-fenfluramine on human experimental anxiety. Psychopharmacology, 127: 276-282.
13. Connel J, Hellewell JSE & Deakin JFW (1994). Effects of a 5HT2c agonist in two models of anxiety in volunteers. Journal of Psychopharmacology, 8: A23 (Abstract).
14. Deakin JFW & Graeff FG (1991). 5-HT and mechanisms of defence. Journal of Psychopharmacology, 5: 305-315.
15. Bel N & Artigas F (1992). Fluvoxamine preferentially increases extra-cellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. European Journal of Pharmacology, 229: 101-103.
16. Mongeau R, Blier P & de Montigny C (1997). The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Research Bulletin, 23: 145-195.
17. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN & Yocca FD (1995). Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. Journal of Clinical Psychiatry, 56 (Suppl 6): 3-11.
18. Silva M, Hetem LA, Guimarães FS & Graeff FG (2001). Opposed effects of nefazodone in two human models of anxiety. Psychopharmacology, 156: 454-460.
19. Ashcroft KR, Guimarães FS, Wang M & Deakin JF (1991). Evaluation of a psychophysiological model of classical fear conditioning in anxious patients. Psychopharmacology, 104: 215-219.
20. Del-Ben CM, Vilela JAA, Hetem LAB, Guimarães FS, Graeff FG & Zuardi AW (2001). Do panic patients process unconditioned fear vs. conditioned anxiety differently than normal subjects? Psychiatry Research, 104: 227-237.
21. Geer JH (1965). The development of a scale to measure fear. Behaviour Research and Therapy, 3: 45-53.
22. McNair DM, Frankenthaler LM, Czerlinsky T, White TW, Sasson S & Fisher S (1982). Simulated public speaking as a model of clinical anxiety. Psychopharmacology, 77: 7-10.
23. Phillips GC, Jones GE, Rieger ER & Snell JB (1997). Normative data for the personal report of confidence as a speaker. Journal of Anxiety Disorders, 11: 215-220.
24. Brunello N, den Boer JA, Judd LL et al. (2000). Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment. Journal of Affective Disorders, 60: 61-74.
25. Furmark T, Tillfors M, Everz P, Marteinsdottir I, Gefvert O & Fredrikson M (1999). Social phobia in the general population: prevalence and sociodemographic profile. Social Psychiatry and Psychiatric Epidemiology, 34: 416-424.
26. Stein MB, Walker JR & Forde DR (1996). Public-speaking fears in a community sample. Prevalence, impact on functioning, and diagnostic classification. Archives of General Psychiatry, 53: 169-174.
27. Palma SM, Guimarães FS & Zuardi AW (1994). Anxiety induced by simulated public speaking and stroop colour word test in healthy subjects: effects of different trait-anxiety levels. Brazilian Journal of Medical and Biological Research, 27: 2895-2902.
28. Guimarães FS, Zuardi AW & Graeff FG (1987). Effect of chlorimipramine and maprotiline on experimental anxiety in humans. Journal of Psychopharmacology, 1: 184-192.
29. Spielberger CD, Gorsuch RI & Lushene RE (1970). Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto, CA, USA.
30. Norris H (1971). The action of sedatives on brainstem oculomotor systems in man. Neuropharmacology, 10: 181-191.
31. Zuardi AW, Cosme RA, Graeff FG & Guimarães FS (1993). Effects of ipsapirone and cannabidiol on human experimental anxiety. Journal of Psychopharmacology, 7: 82-88.
32. Guimarães FS, Zuardi AW, Gentil Filho V & Graeff FG (1988). A importância do treinamento prévio para uma melhor utilização da escala analógica de humor de Norris. Revista da Associação Brasileira de Psiquiatria, 10: 5-7.
33. Graeff FG, Zuardi AW, Giglio JS, Lima Filho EC & Karniol IG (1985). Effect of metergoline on human anxiety. Psychopharmacology, 86: 334-338.
34. Guimarães FS, Kohem CL, Fillmann HS, de Vecino MCA, de Paoli CL, Ribeiro AMS, Teixeira CC & Wannmacher L (1989). A simple simulated public speaking test for evaluating anxiolytic drugs. Brazilian Journal of Medical and Biological Research, 22: 1083-1089.
35. Kapczinski F, Curran HV, Gray J & Lader M (1994). Flumazenil has an anxiolytic effect in simulated stress. Psychopharmacology, 114: 187-189.
36. Guimarães FS, Mbaya OS & Deakin JFW (1997). Ritanserin facilitates anxiety in a simulated public-speaking paradigm. Journal of Psychopharmacology, 11: 225-231.
37. Monteiro-dos-Santos PC, Graeff FG, dos-Santos JE, Ribeiro RP, Guimarães FS & Zuardi AW (2000). Effects of tryptophan depletion on anxiety induced by simulated public speaking. Brazilian Journal of Medical and Biological Research, 33: 581-587.
38. Shansis FM, Busnello JV, Quevedo J, Forster L, Young S, Izquierdo I & Kapczinski F (2000). Behavioural effects of acute tryptophan depletion in healthy male volunteers. Journal of Psychopharmacology, 14: 157-163.
39. Gentil V (1988). The aversive system, 5HT and panic attacks. In: Simon P, Soubrié P & Willocher D (Editors), Animal Models of Psychiatric Disorders. Vol. 1. Karger, Basel, Switzerland, 142-145.
40. Graeff FG (1988). Animal model of aversion. In: Simon P, Soubrié P & Willocher D (Editors), Animal Models of Psychiatric Disorders. Vol. 1. Karger, Basel, Switzerland, 115-141.
41. Graeff FG (1991). Neurotransmitters in the dorsal periaqueductal gray and animal models of panic anxiety. In: Briley M & File SE (Editors), New Concepts in Anxiety. Macmillan Press, London, UK, 288-312.
42. Jansen LM, Gispen-de Wied CC, Van der Gaag RJ, ten Hove F, Willemsen-Swinkels SW, Harteveld E & Van Engeland H (2000). Unresponsiveness to psychosocial stress in a subgroup of autistic-like children, multiple complex developmental disorder. Psychoneuroendocrinology, 25: 753-764.
43. Tulen JH, Moleman P, van Steenis HG & Boomsma F (1989). Characterization of stress reactions to the Stroop Color Word Test. Pharmacology, Biochemistry and Behavior, 32: 9-15.
44. Jensen AR & Rohwer Jr WD (1966). The Stroop color-word test: a review. Acta Psychologica, 25: 36-93.
45. Nakano S, Gillespie HK & Hollister LE (1978). A model for evaluation of antianxiety drugs with the use of experimentally induced stress: Comparison of nabilone and diazepam. Clinical Pharmacology and Therapeutics, 23: 54-62.
46. Leite JR, Seabra M de L, Sartori VA & Andreatini R (1999). The video-recorded Stroop Color-Word Test as a new model of experimentally-induced anxiety. Progress in Neuro-psychopharmacology and Biological Psychiatry, 23: 809-822.
47. Tulen JH, Moleman P, Boomsma F, van Steenis HG & van den Heuij VJ (1991). Dose-dependent effects of intravenous lorazelpam on cardiovascular activity, plasma catecholamines and psychological function during rest and mental stress. Psychopharmacology, 105: 77-83.
48. Brown JS, Kalish HI & Farber IE (1951). Conditioned fear as revealed by the magnitude of startle response to an auditory stimulus. Journal of Experimental Psychology, 41: 317-327.
49. Davis M (1993). Pharmacological analysis of fear-potentiated startle. Brazilian Journal of Medical and Biological Research, 26: 235-260.
50. Grillon C, Ameli R, Woods SW, Merikangas K & Davis M (1991). Fear-potentiated startle in humans: effects of anticipatory anxiety on the acoustic blink reflex. Psychophysiology, 28: 588-595.
51. Grillon C, Ameli R, Foot M & Davis M (1993). Fear-potentiated startle: relationship to the level of state/trait anxiety in healthy subjects. Biological Psychiatry, 33: 566-574.
52. Patrick CJ, Berthot BD & Moore JD (1996). Diazepam blocks fear-potentiated startle in humans. Journal of Abnormal Psychology, 105: 89-96.
53. Bitsios P, Philpott A, Langley RW, Bradshaw CM & Szabadi E (1999). Comparison of the effects of diazepam on the fear-potentiated startle reflex and the fear-inhibited light reflex in man. Journal of Psychopharmacology, 13: 226-234.
54. Riba J, Rodriguez-Fornells A, Urbano G, Morte A, Antonijoan R & Barbanoj MJ (2001). Differential effects of alprazolam on the baseline and fear-potentiated startle reflex in humans: a dose-response study. Psychopharmacology, 157: 358-367.
55. Curtin JJ, Lang AR, Patrick CJ & Stritzke WG (1998). Alcohol and fear-potentiated startle: the role of competing cognitive demands in the stress-reducing effects of intoxication. Journal of Abnormal Psychology, 107: 547-557.
56. Grillon C, Ameli R, Goddard A, Woods SW & Davis M (1994). Baseline and fear-potentiated startle in panic disorder patients. Biological Psychiatry, 35: 431-439.
57. Morgan 3rd CA, Grillon C, Southwick SM, Davis M & Charney DS (1995). Fear-potentiated startle in posttraumatic stress disorder. Biological Psychiatry, 38: 378-385.
58. Grillon C, Dierker L & Merikangas KR (1998). Fear-potentiated startle in adolescent offspring of parents with anxiety disorders. Biological Psychiatry, 44: 990-997.